Anzeige
Mehr »
Freitag, 04.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
134 Leser
Artikel bewerten:
(0)

Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History

WALTHAM, Massachusetts, July 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that for the 11th consecutive year, employees took a day out of the office to roll up their sleeves and volunteer with community organizations across the Greater Boston area as part of what was the company's largest-ever annual day of service - Alkermes in Action. On Thursday, June 27, more than 450 Alkermes employees volunteered to work on various activities supporting 15 local nonprofits that are aligned with the company's values as a corporate citizen.

This year, employees volunteered at service projects to support homeless men and women, shelter programs for women and children, people with disabilities, after school programs and the preservation of public reservation spaces, including with the following nonprofit organizations:

  • Bina Farm Center
  • Boston Health Care for the Homeless Program
  • Massachusetts Coalition for the Homeless
  • The Dimock Center
  • Pine Street Inn
  • Service Dog Project
  • St. Francis House
  • Appleton Farms
  • Boston Community Gardens
  • Chestnut Hill Farm
  • Mary Cummings Park
  • Powisset Farm
  • Rocky Woods
  • West End House Boys & Girls Club
  • Birthday Wishes

Through Alkermes in Action, the company has established meaningful, long-term relationships with many of the nonprofits that have benefited from the program's support.

"Our employees understand the importance of taking time out of our day-to-day roles to interact directly with the communities we live and work in," said Jeff Winton, Senior Vice President of Public Affairs at Alkermes. "Alkermes in Action is a tangible demonstration of the company's commitment to contribute in a meaningful way to our community that goes beyond the medicines we deliver to patients."

Alkermes in Action was conceived organically 11 years ago by members of the Alkermes Human Resources and Legal teams. The early efforts were led by Madeline Coffin, Senior Vice President of Human Resources, Anne Giovanoni, Vice President, Legal, and Shannon Smith, Senior Director, Human Resources, who saw an opportunity to harness their colleagues' considerable energy and enthusiasm for giving back to bolster the company's impact on the local community. This group was joined by Colleen Ellwanger, Vice President, Program Management, and Don Ellwanger, Director, Facility Systems, whose efforts have elevated Alkermes in Action to become one of the signature events on the company calendar.

"From its inception, Alkermes in Action has embodied the grassroots spirit of our employees and their hands-on approach to making a difference in the community," said Coffin. "It's been amazing to see the momentum the program has gained over the last decade and the impact it has had on shaping a culture of compassion within the company."

The Alkermes in Action volunteer initiative is an important part of the company's broader commitment to social impact, along with the Alkermes Inspirations Grants and Alkermes Pathways Research Awards programs. In addition to its employees located in Waltham, employees at Alkermes' locations in Wilmington, Ohio, Athlone, Ireland, and Dublin, Ireland, as well as the company's field-based employees across the United States, have been active in giving back to the community through volunteerism.

About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases and oncology. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, multiple sclerosis and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Vince Azar, +1 781 609 6468

Alkermes plc Logo

Logo - https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg

© 2019 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.